EUVIMEDScopri EUVIMED
Multizentrische StudieOpen access · CC BY-NC 4.0

Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection

Lukas K van Vugt iD, Erzsi Tegzess iD, Marieke van der Zwan iD, Marian C Clahsen-van Groningen iD, Brenda C M de Winter iD, Priya Vart iD, Marlies E J Reinders iD, Jan Stephan F Sanders iD, Stefan P Berger iD, Dennis A Hesselink iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.70046 ↗

At a glance

Multizentrische Studie in Clinical Transplantation, 2024. Written by Lukas K van Vugt and 9 co-authors. Institution: Erasmus MC Transplant Institute, Rotterdam, The Netherlands. Major MEDLINE topics: Alemtuzumab, Graft Rejection, Kidney Transplantation, Antilymphocyte Serum. Cited 5 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Alemtuzumab can be an alternative to rabbit anti‐thymocyte globulin (rATG) to treat severe or glucocorticoid‐resistant acute T cell‐mediated kidney transplant rejection (TCMR). Yet, there are few reports in which these two treatments are evaluated let alone, compared. This study describes the real‐world clinical experience of both therapies and compares their efficacy and toxicity.

Methods

Kidney transplant recipients of two Dutch transplant centers who received lymphocyte‐depleting antibody therapy for severe or glucocorticoid‐resistant TCMR were retrospectively evaluated. In the first, alemtuzumab was the standard treatment for this indication, in the second, it was rATG. Patient survival, graft survival and function, and the occurrence of infections and malignancies were reported and compared.

Results

One hundred and forty‐three patients treated with alemtuzumab and 57 patients with rATG were evaluated. Patient survival was not significantly different during follow‐up ( p = 0.55), and 5‐year survival rates were 71.0% (95% confidence interval [CI]: 63.0–79.9) after alemtuzumab and 70.7% (95% CI: 58.3–85.7) after rATG. Graft survival was not significantly different during follow‐up either ( p = 0.24), and 5‐year graft loss rates were 32.3% (95% CI: 24.2–40.5) after alemtuzumab and 29.2% (95% CI: 16.0–42.4) after rATG. The occurrence of infections and malignancies did not differ between groups.

Conclusion

Mostly, severe TCMRs have good long‐term graft survival and function after either alemtuzumab or rATG therapy. No significant differences between the two therapies were found in this real‐world clinical experience. Alemtuzumab is an effective alternative to rATG for the treatment of severe TCMR.

Subjects

MeSH terms (MEDLINE)

AlemtuzumabGraft RejectionKidney TransplantationAntilymphocyte SerumGraft SurvivalT-LymphocytesHumansMaleFemaleMiddle AgedRetrospective StudiesFollow-Up StudiesSurvival RateAdultPrognosisKidney Failure, ChronicKidney Function TestsImmunosuppressive AgentsPostoperative ComplicationsRisk FactorsGlomerular Filtration Rate

Author keywords

T cell‐mediated kidney transplant rejectionalemtuzumabefficacyrabbit anti‐thymocyte globulintoxicity

Substances

AlemtuzumabAntilymphocyte SerumImmunosuppressive Agents

Authors and institutions

  • Erasmus MC Transplant Institute, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Internal Medicine, Albert Schweitzer Hospital Dordrecht, Dordrecht, The Netherlands.
  • Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Institute of Experimental Medicine and Systems Biology, RWTH Aachen University, Aachen, Germany.

ORCID profiles: Lukas K van Vugt, Erzsi Tegzess, Marieke van der Zwan, Marian C Clahsen-van Groningen, Brenda C M de Winter, Priya Vart, Marlies E J Reinders, Jan Stephan F Sanders, Stefan P Berger, Dennis A Hesselink

Cite

APA

van Vugt, L. K., Tegzess, E., van der Zwan, M., Clahsen-van Groningen, M. C., de Winter, B. C. M., Vart, P., Reinders, M. E. J., Sanders, J. S. F., Berger, S. P., & Hesselink, D. A. (2024). Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection. Clinical Transplantation. https://doi.org/10.1111/ctr.70046

Vancouver

van Vugt LK, Tegzess E, van der Zwan M, Clahsen-van Groningen MC, de Winter BCM, Vart P, et al. Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection. Clinical Transplantation. 2024. doi:10.1111/ctr.70046

BibTeX
@article{vanVugt2024,
  author = {van Vugt, Lukas K and Tegzess, Erzsi and van der Zwan, Marieke and Clahsen-van Groningen, Marian C and de Winter, Brenda C M and Vart, Priya and Reinders, Marlies E J and Sanders, Jan Stephan F and Berger, Stefan P and Hesselink, Dennis A},
  title = {Multicenter, Real‐World Clinical Evaluation of Alemtuzumab and Anti‐Thymocyte Globulin for Severe Acute T Cell‐Mediated Kidney Transplant Rejection},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.70046}
}
Start for free →